---
title: "Analyst Reiterates Buy on Trulieve, Maintains $19 Price Target on Strong Profitability and Cash Generation"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285601985.md"
description: "Analyst Neal Gilmer from Haywood has reiterated a Buy rating on Trulieve Cannabis, maintaining a price target of C$19.00. This decision is based on the company's strong profitability and cash generation, despite modest revenue pressure. Trulieve exceeded revenue expectations in Q1/26, delivered solid adjusted EBITDA, and maintained robust margins. The company's extensive retail presence and brand strength, along with a healthy cash balance, position it well for future growth opportunities."
datetime: "2026-05-07T18:55:47.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285601985.md)
  - [en](https://longbridge.com/en/news/285601985.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285601985.md)
---

# Analyst Reiterates Buy on Trulieve, Maintains $19 Price Target on Strong Profitability and Cash Generation

Trulieve Cannabis, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Neal Gilmer from Haywood maintained a Buy rating on the stock and has a C$19.00 price target.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Neal Gilmer has given his Buy rating due to a combination of factors including Trulieve’s resilient profitability and strong cash generation despite modest top-line pressure. The company modestly surpassed revenue expectations in Q1/26 and delivered adjusted EBITDA above both his estimate and consensus, while sustaining robust margins around the mid-30% range and generating solid free cash flow that strengthened its liquidity profile.

He also highlights the company’s substantial retail footprint and brand strength, with retail sales representing the bulk of revenue and customer retention remaining high even as sales dipped year over year. The continued expansion of dispensaries, particularly in Florida, along with a sizeable cash balance relative to its debt, underpins his view that Trulieve is well positioned to capitalize on growth opportunities and supports maintaining a $19 price target.

### Related Stocks

- [TCNNF.US](https://longbridge.com/en/quote/TCNNF.US.md)

## Related News & Research

- [Pizza Pizza Royalty slashes monthly dividend by 12.9% to CAD 0.0675 a share](https://longbridge.com/en/news/286714154.md)
- [Do Wall Street Analysts Like Darden Restaurants Stock?](https://longbridge.com/en/news/286675237.md)
- [Walmart Stock: Here’s Why Analysts Are Raising Price Targets Before Q1 Earnings.](https://longbridge.com/en/news/286950969.md)
- [Q2 EPS Forecast for Avalo Therapeutics Boosted by Analyst](https://longbridge.com/en/news/286903837.md)
- [Analyst Reiterates Buy on Dermata, Keeps 12-Month Price Target Unchanged at $4](https://longbridge.com/en/news/286958909.md)